Pharmacological agents for the treatment of adult attention deficit hyperactivity disorder: A review of the literature

Journal of Pharmacy Practice

Volumn 19, Issue 6, 2006, Pages 336-341

  Sherwood, Devon A ^a   Rey, Jose A ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Adult ADHD; Alpha 2 agonists; Antidepressants; Atomoxetine; Stimulants

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; CENTRAL STIMULANT AGENT; CLONIDINE; DESIPRAMINE; DEXAMPHETAMINE; DEXEDRINE SPANSULE; DEXMETHYLPHENIDATE; FOCALIN XR; GUANFACINE; IMIPRAMINE; METHYLIN ER; METHYLPHENIDATE; MODAFINIL; PLACEBO; PSYCHOSTIMULANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE;

ABDOMINAL PAIN; ADJUVANT THERAPY; ANOREXIA; ANXIETY; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; CONSTIPATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; HEADACHE; HEART PALPITATION; HUMAN; INSOMNIA; IRRITABILITY; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; NAUSEA; NERVOUSNESS; NONHUMAN; RECOMMENDED DRUG DOSE; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; URINE RETENTION; XEROSTOMIA;

EID: 34249652980     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190007300727     Document Type: Review

References (36)

1. Faraone SV, Spencer TJ, Montano B., et al. Attention-deficit/ hyperactivity disorder in adults: a survey of current practice in psychiatry and primary care. Arch Intern Med. 2004 ; 164 (11). 1221-1226.
2. Okie S. ADHD in adults. N Eng J Med. 2006 ; 354 (25). 2637-2641.
3. Kessler RC, Adler L., Barkley R., et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey replication. Am J Psychiatry. 2006 ; 163 (4). 716-723.
4. Biederman J. Pharmacotherapy for attention deficit hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD. J Clin Psychiatry. 2003 ; 64 (S11): 3-8.
5. Faraone SV, Spencer T., Aleardi M., et al. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/ hyperactivity disorder. J Clin Psychopharmacol. 2004 ; 24 (1). 24-29.
6. Clark L., Blackwell AD, Aron Ar, et al. Association between response inhibition and working memory in adult ADHD: a link to right frontal cortex pathology ? Biol Psychiatry. 2006 ; in press.
7. Wilens TE, Faraone SV, Biederman J. Attention-deficit/ hyperactivity disorder in adults. JAMA. 2004 ; 292 (5). 619-623.
8. FDA Center for Drug Evaluation and Research. Alert for healthcare professionals-pemoline tablets and chewable tablets (marketed as CYLERT); FDA Alert [10/2005]: Liver injury risk and market withdrawal. Medical Review [Online]. Available at: http://www.fda.gov. Accessed October 23, 2006.
9. Bender L., Cottington F. The use of amphetamine sulfate (Benzedrine) in child psychiatry. Am J Psychiatry. 1942 ; 99 (1). 16-121.
10. Laufer M., Denhoff E., Solomons G. Hyperkinetic impulse disorder in children's behavior problems. Psychosom Med. 1957 ; 19 (1). 38-49.
11. Greenhill LL, Pliszka S., Dulcan Mk, et al. Summary of the practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2001 ; 40 (11). 1352-1355.
12. Gibson AP, Bettinger TL, Patel NC, et al. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder. Ann Pharmacother. 2006 ; 40 (6). 1134-1142.
13. Wigal S., Swanson JW, Feifel D., et al. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-thre-methylphenidate hydrochloride in children with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2004 ; 43 (11). 1406-1414.
14. Adis R&D Profile-dexmethylphenidate. Drugs R&D. 2002 ; 3 (4). 279-282.
15. Focalin™ (dexmethylphenidate) package insert. Gainesville, Ga: Novartis Pharmaceuticals Corp; 2006.
16. Mannheim GB Clinical review (NDA on SparlonTM). FDA Center for Drug Evaluation and Research. Available at: http://www.fda.gov/ohrms/dockets/ac/06/ briefing/2006-4212b1-01-02-FDA-Tab2.pdf. Accessed October 24, 2006.
17. Simpson D., Plosker GL Adis drug evaluation-atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs. 2004 ; 64 (2). 205-222.
18. Adler L., Dietrich A., Reimherr FW, et al. Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD. Ann Clin Psychiatry. 2006 ; 18 (2). 107-113.
19. Wernicke JF, Adler L., Spencer T., et al. Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. J Clin Psychopharmacol. 2004 ; 24 (1). 30-35.
20. Caballero J., Nahata MC Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder. Clin Ther. 2003 ; 25 (12). 3065-3083.
21. Turner DC, Clark L., Dowson J., et al. Modafinil improves cognition and response inhibition in adult attention-deficit/ hyperactivity disorder. Biol Psychiatry. 2004 ; 55 (10). 1031-1040.
22. Wilens TE, Biederman J., Prince J., et al. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry. 1996 ; 153 (9). 1147-1153.
23. Maidment ID The use of antidepressants to treat attention deficit hyperactivity disorder in adults. J Psychopharmacol. 2003 ; 17 (3). 332-336.
24. Higgins ES A comparative analysis of antidepressants and stimulants for the treatment of adults with attention-deficit hyperactivity disorder. J Fam Pract. 1999 ; 48 (1). 15-20.
25. Wilens TE, Spencer T., Biederman J., et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry. 2001 ; 158 (2). 282-288.
26. Kuperman S., Perry PJ, Gaffney GR, et al. Bupropion SR versus methylphenidate versus placebo for attention deficit hyperactivity disorder in adults. Ann Clin Psychiatry. 2001 ; 13 (3). 129-134.
27. Wender PH, Reimherr FW Bupropion treatment of attention-deficit hyperactivity disorder in adults. Am J Psychiatry. 1990 ; 147 (8). 1018-1020.
28. Upadhyaya HP, Brady KT, Sethuraman G., et al. Venlafaxine treatment of patients with comorbid alcohol/cocaine abuse and attention-deficit hyperactivity disorder: a pilot study. J Clin Psychopharmacol. 2001 ; 21 (1). 116-118.
29. Hornig-Rohan M., Amsterdam JD Venlafaxine versus stimulant therapy in patients with dual diagnosis ADD and depression. Prog Neuropsychopharmacol Biol Psychiatry. 2002 ; 26 (3). 585-589.
30. Hedges D., Reimherr FW, Rogers A., et al. An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder. Psychopharmacol Bull. 1995 ; 31 (4). 779-783.
31. Adler LA, Resnick S., Kunz M., et al. Open-label trial of venlafaxine in adults with attention deficit disorder. Psychopharmacol Bull. 1995 ; 31 (4). 785-788.
32. Findling RL, Schwartz MA, Flannerly DJ, et al. Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial. J Clin Psychiatry. 1996 ; 57 (5). 184-189.
33. Reimherr FW, Hedges DW, Strong RE An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder. Psychopharmacol Bull. 1995 ; 31: 609.
34. Xu C., Schachar R., Tannock R., et al. Linkage study of alpha-2a adrenergic receptor in attention-deficit hyperactivity disorder families. Am J Med Genet. 2001 ; 105 (2). 159-162.
35. Hunt RD, Arnsten AF, Asbell MD An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1995 ; 34 (1). 50-54.
36. Taylor FB, Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2001 ; 21 (2). 223-228.